Abstract:From the 33,000 men in the U.S. who die from prostate cancer each year, the majority of these patients exhibit metastatic disease with bone being the most common site of metastasis. Prostate cancer bone metastases are commonly blastic, exhibiting new growth of unhealthy sclerotic bone, which can cause painful skeletal related events. Patient's current care entails androgen deprivation therapy, anti-resorptive agents, radiation, and chemotherapy to help control the spread of the cancer but little intervention is available to treat blastic bone disease. The transforming growth factor beta (TGFβ) and bone morphogenetic protein (BMP) pathways are known to regulate bone growth and resorption of destructive lytic bone lesions, yet the role of TGFβ/BMP signaling in prostate cancer blastic vs lytic bone lesions are not fully understood. We hypothesized that to target the BMP/TGFβ pathway, a useful biomarker of bone lytic or blastic pathology would have superior response. We show distinct BMP vs. TGFβ signaling in clinical samples of human prostate cancer bone metastases with either lytic or blastic pathologies. BMPs exhibit distinct effects on bone homeostasis, so to examine the effect of BMP inhibition on healthy bone, we treated mice with the BMP receptor small molecule antagonist DMH1 and saw a modest temporary improvement in bone health, with increased trabecular bone. We next sought to use the BMP inhibitor DMH1 to treat bone metastasis engraftment seeded by a caudal artery injection of the lytic human prostate cell line PC3 in immunodeficient mice. The colonization by PC3 cells to the bone were restricted with DMH1 treatment and bone health was importantly preserved. We next proceeded to test BMP inhibition in an injury model of established bone metastasis via intratibial injection of the MYC-CaP mouse prostate cell line into FVBN syngeneic mice. DMH1 treated mice had a modest decrease in trabecular bone and reduced lymphocytes in circulation without affecting tumor growth. Taken together we show unique responses to BMP inhibition in metastatic prostate cancer in the bone. These studies suggest that profiling bone lesions in metastatic prostate cancer can help identify therapeutic targets that not only treat the metastatic tumor but also address the need to better treat the distinct tumor induced bone disease.

Bone Morphogenetic Proteins and Their Receptor Signaling in Prostate Cancer.

Tgf-Beta and Bmp Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease

Bone morphogenetic protein and bone metastasis, implication and therapeutic potential.

Bone Morphogenetic Proteins, Breast Cancer, and Bone Metastases: Striking the Right Balance

When BMP Signalling Goes Wrong: the Intracellular and Molecular Mechanisms of BMP Signalling in Cancer

Biological Roles of Human Bone Morphogenetic Protein 9 in the Bone Microenvironment of Human Breast Cancer MDA-MB-231 Cells.

Bone Morphogenetic Proteins in Tumour Associated Angiogenesis and Implication in Cancer Therapies

Bone morphogenetic proteins mediate crosstalk between cancer cells and the tumour microenvironment at primary tumours and metastases (Review)

BMP9 Regulates Cross-Talk Between Breast Cancer Cells and Bone Marrow-Derived Mesenchymal Stem Cells.

Roles of Bone Morphogenetic Proteins and Their Receptors in Mammalian Reproduction

Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases Through A Dual Mechanism

Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease

Bone Morphogenetic Proteins In The Initiation And Progression Of Breast Cancer

[BMPs and cancer].

Bone Morphogenetic Protein-9 Induces Apoptosis in Prostate Cancer Cells, the Role of Prostate Apoptosis Response-4

Vascular Endothelial Growth Factor Contributes To The Prostate Cancer-Induced Osteoblast Differentiation Mediated By Bone Morphogenetic Protein

Aberrant Expression of Bone Morphogenetic Proteins in the Disease Progression and Metastasis of Breast Cancer

Bone morphogenetic protein 1: a prognostic indicator and potential biomarker in three cancer types

TGF-β and BMP7 Interactions in Tumour Progression and Bone Metastasis

Hepatocyte Growth Factor Up-Regulates the Expression of the Bone Morphogenetic Protein (BMP) Receptors, BMPR-IB and BMPR-II, in Human Prostate Cancer Cells.

Bone Morphogenetic Protein-10 Suppresses the Growth and Aggressiveness of Prostate Cancer Cells Through a Smad Independent Pathway.